Integrating Novel Agents Earlier in the Treatment of HL

Dr. Alex Herrera – City of Hope (Duarte, California)

About Speaker

Dr. Alex Herrera – City of Hope

Alex Herrera, M.D., earned his undergraduate degree summa cum laude from Princeton University and received his medical degree from Harvard Medical School. Dr. Herrera completed his residency in internal medicine at the Brigham and Women’s Hospital, before pursuing a hematology-oncology fellowship at the Dana-Farber Cancer Institute/Massachusetts General Hospital. He completed a bone marrow transplant fellowship at City of Hope where he stayed on as an Assistant Professor in the Department of Hematology and Hematopoietic Cell Transplantation. Dr. Herrera’s clinical and research interests center on immunotherapy and hematopoietic stem cell transplantation in patients with lymphoma. He leads several clinical trials evaluating immune checkpoint inhibitors and other novel agents for the treatment of relapsed or refractory non-Hodgkin lymphoma or classical Hodgkin lymphoma and in lymphoma patients undergoing hematopoietic stem cell transplantation. He also studies biomarkers of response and outcome in patients with lymphoma treated with immunotherapies or hematopoietic stem cell transplantation, including immunohistochemical and cytogenetic biomarkers and sequencing-based circulating tumor DNA detection, as well as gene expression, mutational profiling, and quantitative spatial immunofluorescence of tumor cells and the tumor microenvironment to identify biomarkers predictive of response to a treatment. The goal of these studies is to identify target populations for enrollment in rational prospective clinical trials using biomarker-based interventions to improve outcomes.

Thank you to our WHU 2021 Sponsors